Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine

Chemico-Biological Interactions

Volumn 118, Issue 2, 1999, Pages 171-189

  Tugnait, Meera ^a   Hawes, Edward M ^a   McKay, Gordon ^a   Eichelbaum, Michel ^b   Midha, Kamal K ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b ROBERT BOSCH GMBH   (Germany)

Author keywords

Clozapine; CYP1A2; CYP3A4; Cytochromes P450; N demethylation; N oxidation

Indexed keywords

CLOZAPINE; CYTOCHROME P450;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG DETERMINATION; DRUG OXIDATION; ENZYME CONFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METABOLISM;

ANTIBODIES; ANTIPSYCHOTIC AGENTS; CELL LINE; CLOZAPINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GENE EXPRESSION; HUMANS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE;

EID: 0032955464     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(99)00006-X     Document Type: Article

References (39)

1. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
2. Krupp P., Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology. 99:1989;S118-S121.
3. Pisciotta A.V., Konings S.A., Ciesemier L.L., Cronkite C.E., Lieberman J.A. Cytotoxicity activity in serum of patients with clozapine-induced agranulocytosis. J. Lab. Clin. Med. 119:1992;254-266.
4. Fischer V., Haar J.A., Greiner L., Lloyd R.V., Mason R.P. Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis. Mol. Pharmacol. 40:1991;846-853.
5. Park B.K., Pirmohamed M., Kitteringham N.R. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 34:1992;377-395.
6. Liu Z.C., Uetrecht J.P. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther. 275:1995;1476-1483.
7. Uetrecht J.P. Myeloperoxidase as a generator of drug free radicals. Biochem. Soc. Symp. 61:1995;163-170.
8. Fitton A., Heel R.C. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs. 40:1990;722-747.
9. Jann M.W., Grimsley S.R., Gray E.C., Chang W.-H. Pharmacokinetics and pharmacodynamics of clozapine. Clin. Phamacokinet. 24:1993;161-176.
10. Dain J.G., Nicoletti J., Ballard F. Biotransformation of clozapine in humans. Drug Metab. Dispos. 25:1997;603-609.
11. 3- bei der metabolisierung des clozapins im menschlichen körper. Arzneim.-Forsch. 27:1977;982-990.
12. +-glucuronide in the urine of patients treated with clozapine using electrospray mass spectrometry. Biol. Mass Spectrom. 23:1994;147-148.
13. Pirmohamed M., Williams D., Madden S., Templeton E., Park B.K. Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272:1995;984-990.
14. Zhang G.-Q., McKay G., Hubbard J.W., Midha K.K. Application of electrospray mass spectrometry in the identification of intact glucuronide and sulphate conjugates of clozapine in rat. Xenobiotica. 26:1996;541-550.
15. Fischer V., Vogels B., Maurer G., Tynes R.E. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 260:1992;1355-1360.
16. Ring B.J., Binkley S.N., Vandenbranden M., Wrighton S.A. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br. J. Clin. Pharmacol. 41:1996;181-186.
17. Tugnait M., Hawes E.M., McKay G., Rettie A.E., Haining R.L., Midha K.K. N-Oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab. Dispos. 25:1997;524-527.
18. Dahl M.-L., Llerena A., Bondesson U., Lindstrom L., Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br. J. Clin Pharmacol. 37:1994;71-74.
19. Arranz M.J., Dawson E., Shaikh S., Sham P., Sharma T., Aitchison K., Crocq M.A., Gill M., Kerwin R., Collier D.A. Cytochrome P4502D6 genotype does not determine response to clozapine. Br. J. Clin. Pharmacol. 39:1995;417-420.
20. Brosen K., Skjelbo E., Rasmussen B.B., Poulsen H.E., Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45:1993;1211-1214.
21. Hiemke C., Weigmann H., Härtter S., Dahmen N., Wetzel H., Müller H. Elevated plasma levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol. 14:1994;279-281.
22. Jerling M., Lindstrom L., Bondesson U., Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther. Drug Monit. 16:1994;368-374.
23. Bertilsson L., Carrillo J.A., Dahl M.-L., Llerena A., Alm C., Bondesson U., Lindstrom L., de la Rubia I.R., Ramos S., Benitez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38:1994;471-473.
24. Raitasuo V., Lehtovaara R., Huttunen M.O. Carbamazepine and plasma levels of clozapine. Am. J. Psychiatry. 150:1993;169.
25. Lin G., McKay G., Midha K.K. Characterization of metabolites of clozapine N-oxide in the rat by micro-column high performance liquid chromatography/mass spectrometry with electrospray interface. J. Pharm. Biomed. Anal. 14:1996;1561-1577.
26. Meier P.J., Muller H.K., Dick B., Meyer U.A. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gasteroenterology. 85:1983;682-692.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 93:1951;265-275.
28. Botsch S., Gautier J.-C., Beaune P., Eichelbaum M., Kroemer H.K. Identification and characterization of the cytochrome P-450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 43:1993;120-126.
29. Baldwin S.J., Bloomer J.C., Smith G.J., Ayrton A.D., Clarke S.E., Chenery R.J. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica. 25:1995;261-270.
30. Newton D.J., Wang R.W., Lu A.Y.H. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23:1995;154-158.
31. Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F.J., Tsatsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica. 26:1996;681-693.
32. Eiermann B., Engel G., Johansson I., Zanger U.M., Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br. J. Clin. Pharmacol. 44:1997;439-446.
33. Wang R.W., Liu L., Cheng H. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab. Dispos. 24:1996;786-791.
34. Coutts R.T., Su P., Baker G.B., Daneshtalab M. Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observations on metabolite stability. J. Chromatogr. Biomed. Appl. 615:1993;265-272.
35. Lemoine A., Gautier J.C., Azoulay D., Kiffel L., Belloc C., Guengerich F.P., Maurel P., Beaune P., Leroux J.P. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43:1993;827-832.
36. Linnet K., Olesen O.V. Metabolism of clozapine by cDNA expressed human cytochrome P450 enzymes. Drug Metab. Dispos. 25:1997;1379-1382.
37. Funderburg L.G., Vertrees J.E., True J.E., Miller A.L. Seizure following addition of erythromycin to clozapine treatment. Am. J. Psychiatry. 151:1994;1840-1841.
38. Cohen L.G., Chesley S., Eugenio L., Flood J.G., Fisch J., Goff D.C. Erythromycin-induced clozapine toxic reaction. Arch. Intern. Med. 156:1996;675-677.
39. Haring C., Fleischhaker W.W., Schett P., Humpel C., Barnas C., Saria A. Influence of patient-related variables on clozapine plasma levels. Am. J. Psychiatry. 147:1990;1471-1475.